Phase Ib/II study of the safety and efficacy of combination therapy with multikinase vascular endothelial growth factor inhibitor Pazopanib and MEK inhibitor Trametinib in advanced soft tissue sarcoma

PURPOSE: Pazopanib, a multi-receptor tyrosine kinase inhibitor targeting primarily vascular endothelial growth factor receptors 1-3 (VEGFRs1-3), is approved for advanced soft tissue sarcoma and renal cell cancer. Downstream of VEGFR, trametinib is an FDA-approved MEK inhibitor used for melanoma. We...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Clin Cancer Res
Main Authors: Subbiah, Vivek, Meyer, Christian, Zinner, Ralph, Meric-Bernstam, Funda, Zahurak, Marianna, O’Connor, Ashley, Roszik, Jason, Shaw, Kenna, Ludwig, Joseph, Kurzrock, Razelle, Azad, Nilofer
Formáid: Artigo
Teanga:Inglês
Foilsithe: 2017
Ábhair:
Article
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5754188/
https://ncbi.nlm.nih.gov/pubmed/28377484
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0272
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla